ArticleTomography (Ann Arbor, Mich.)2026
HAAU-Net: Hybrid Adaptive Attention U-Net Integrated with Context-Aware Morphologically Stable Features for Real-Time MRI Brain Tumor Detection and Segmentation.
Article in Tomography (Ann Arbor, Mich.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An Efficient Cross-Modal Interaction and Dynamic Fusion Network for Multimodal Breast Ultrasound Diagnosis.Tomography (Ann Arbor, Mich.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe Magnetic Resonance Imaging (MRI)-based tumor segmentation remains a challenging problem in medical imaging due to tumor heterogeneity, unpredictable morphological features, and the high complexity of calculations needed to implement it in clinical practice, putting it out of the scope of real-time applications. Although neural networks have significantly improved segmentation performance, they still struggle to capture morphological tumor features while maintaining computational efficiency. This work introduces Hybrid Adaptive Attention U-Net (HAAU-Net) framework, combining context-aware morphologically stable features and spatial channel attention to achieve high-quality tumor segmentation with less computational cost.
methodsThe proposed HAAU-Net framework integrates multi-scale Adaptive Attention Blocks (AAB), Context-Aware Morphological Feature Module (CAMFM) and Spatial-Channel Hybrid Attention Mechanism (SCHAM). CAMFM is used to maintain the stability of morphological features by hierarchical aggregation and dynamic normalization of features. SCHAM enhances feature representation by modelling channels and spatial regions where the strongest feature are determined to use in segmentation. On the BRaTS 2022/2023 data, the proposed HAAU-Net is evaluated using four modalities including T1, T1GD, T2 and T2-FLAIR sequences.
resultsThe proposed model able to obtain 96.8% segmentation accuracy with a Dice coefficient of 0.89 on the entire tumor region, outperforming the alternative U-Net (0.83) and conventional CNN methods of segmentation (0.81). The proposed HAAU-Net architecture cuts the computational complexity of the standard deep learning models by 43% and still achieve real-time inference (28 FPS on a regular GPU). The hybrid model used to predict survival has a C-Index of 0.91 which is higher than the traditional SVM-based methods (0.72).
conclusionsSpatial-channel attention, combined with morphologically stable features, can be combined to allow clinically significant interpretability in attention maps. The proposed framework significantly improves segmentation performance while maintaining computational effeciency. This broad system has a serious potential of AI-enabled clinical decision support system and early prognostic diagnosis in neuro-oncology with practical deployment capability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.